President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

UNICEF’s work to improve care for children living with NCDs in Zimbabwe helped Kelly, 10, receive diabetes diagnosis and treatment.

Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699.

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Gov. Mike Braun visited Lebanon Tuesday to help break ground for the $4.5 billion Eli Lilly Medicine Foundry in Lebanon. The foundry is the first research and development site of its kind in the world ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.